Abstract:Objective: Mutations in members of the cytoskeletal intermediate filament proteins (IFs), keratin polypeptides 8 and 18 (K8/K18), predispose their carriers to acute and chronic liver disease progression.Keratin associated diseases are among .70human diseases that are caused or predisposed to by IF mutations, with the defining feature in many of these diseases being disruption of the normal IF organization within the cytoplasm.In contrast to microfilaments and microtubules, no drugs are available for IFs that can modulate their organization and potentially provide a sorely lacking therapy.Methods: We used an imagingbased drug screening platform consisting of lung carcinoma A549 cells transduced with lentiviruses containing GFP-tagged K18 R90C and wild-type K8.The cells were screened against several compound libraries, and a select compound was further tested in cell culture and in livers of mice that express mutant K18 in order to define its mechanism of action.Results: Screening of a 320-compound kinase inhibitor library showed that the inhibitors of protein kinase C (PKC) and tyrosine kinases, particularly MIDOSTAURIN, led to significant correction of the defective organization of K18 R90C puncta towards normal filaments after 24 h with a maximal effect at 48 h.The findings were confirmed using multiple MIDOSTAURIN concentrations and in another cell line, Hacat, that expresses mutant K14.While MIDOS-TAURIN diminished the expression of the mutant keratin 14 in Hacat cells, the effect in the A549 cells was independent of K18 expression but causes changes in K18 phosphorylation that are known to regulate filament formation.MIDOSTAURIN significantly prevented interferon and FAS ligand-induced apoptosis in A549 cells.The protective effect occurs after 48 h but not after 1 h treatment with MIDOSTAURIN, suggesting that the drug effect is more likely to be related to the correction of filament organization.In mice, administration of MIDOSTAURIN is well tolerated and its administration prior to exposure to FAS results in dramatic protection from liver injury.Conclusion: The kinase inhibitor MIDOSTAURIN alleviates cytoskeletal structural defects caused by K18 R90C mutation and also protects from apoptosis in cultured and in the livers of mice exposed to FAS ligand.MIDOSTAURIN may be a potential therapeutic for IF diseases and, notably, it is presently undergoing clinical trials in patients with acute myeloid leukemia and gastrointestinal stromal tumors.

High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins.

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Mo1772 Kinase Inhibition Normalizes Mutation-Mediated Keratin Filament Disruption and Predisposition to Apoptosis and Liver Injury

High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway

Identification of the KIF18A alpha-4 helix as a therapeutic target for chromosomally unstable tumor cells

A plant flavonol and genetic suppressors rescue a pathogenic mutation associated with kinesin in neurons

A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening

Abstract 5723: Selectivity profiling of small molecule kinesin inhibitors using microplate-based ATPase activity assay

Establishment of Platform for Screening Insulin-Like Growth Factor-1 Receptor Inhibitors and Evaluation of Novel Inhibitors

Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction

Optogenetic and chemical genetic tools for rapid repositioning of vimentin intermediate filaments

Development of a time-resolved fluorescence resonance energy transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction

[Establishment of High-Throughput Drug Screening Cell Models Based on JAK-STAT Signal Pathway].

High-throughput screening normalized to biological response: application to antiviral drug discovery

PKC412 Normalizes Mutation‐related Keratin Filament Disruption and Hepatic Injury in Mice by Promoting Keratin–myosin Binding

Discovery of Natural Product ITPK1 Inhibitors using a Luciferase-Based High-Throughput Screen

High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery

A scalable human iPSC-based neuromuscular disease model on suspended biobased elastomer nanofiber scaffolds

High-Throughput Image-Based Assay for Identifying In Vitro Hepatocyte Microtubule Disruption

Computational screening of biomarkers and potential drugs for arthrofibrosis based on combination of sequencing and large nature language model

A molecular imaging biosensor detects in vivo protein folding and misfolding